Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Other Non-Current Liabilities (2021 - 2026)

Atara Biotherapeutics filings provide 6 years of Other Non-Current Liabilities readings, the most recent being $41.5 million for Q1 2026.

  • On a quarterly basis, Other Non-Current Liabilities rose 1226.32% to $41.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $41.5 million, a 1226.32% increase, with the full-year FY2025 number at $42.4 million, up 8.76% from a year prior.
  • Other Non-Current Liabilities hit $41.5 million in Q1 2026 for Atara Biotherapeutics, down from $42.4 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $42.4 million in Q4 2025 to a low of $616000.0 in Q1 2022.
  • Median Other Non-Current Liabilities over the past 5 years was $5.2 million (2023), compared with a mean of $14.6 million.
  • Biggest five-year swings in Other Non-Current Liabilities: plummeted 55.58% in 2025 and later skyrocketed 1226.32% in 2026.
  • Atara Biotherapeutics' Other Non-Current Liabilities stood at $5.6 million in 2022, then surged by 530.41% to $35.1 million in 2023, then grew by 11.2% to $39.0 million in 2024, then grew by 8.76% to $42.4 million in 2025, then decreased by 2.24% to $41.5 million in 2026.
  • The last three reported values for Other Non-Current Liabilities were $41.5 million (Q1 2026), $42.4 million (Q4 2025), and $1.8 million (Q3 2025) per Business Quant data.